Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Ruff

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
The Oncologist|March 11, 2022
The Impact of Breast Cancer Treatment Delays on Survival Among South African WomenYoanna S Pumpalova, Oluwatosin A Ayeni, Wenlong Carl Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME studyJean-Yves Douillard, Salvatore Siena, James Cassidy, et al.
Plos One|February 16, 2023
Drivers of disparities in stage at diagnosis among women with breast cancer: South African breast cancers and HIV outcomes cohortWitness Mapanga, Shane A Norris, Ashleigh Craig, et al.
International Journal of Cancer|February 26, 2022
Impact of HIV infection on survival among women with stage I-III breast cancer: Results from the South African breast cancer and HIV outcomes studyOluwatosin A Ayeni, Daniel S O'Neil, Yoanna S Pumpalova, et al.
The Oncologist|March 21, 2023
The Impact of HIV Infection on Neoadjuvant and Adjuvant Chemotherapy Relative Dose Intensity in South African Patients with Breast CancerDaniel S O'Neil, Oluwatosin A Ayeni, Hayley A Farrow, et al.
The Lancet. Global Health|November 22, 2024
The association of HIV status with triple-negative breast cancer in patients with breast cancer in South Africa: a cross-sectional analysis of case-only data from a prospective cohort studyJacob Dubner, Alfred I Neugut, Maureen Joffe, et al.
Breast Cancer Research : BCR|January 23, 2023
Multimorbidity and overall survival among women with breast cancer: results from the South African Breast Cancer and HIV Outcomes StudyOluwatosin A Ayeni, Maureen Joffe, Witness Mapanga, et al.
The New England Journal of Medicine|September 13, 2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancerJean-Yves Douillard, Kelly S Oliner, Salvatore Siena, et al.
Targeted Oncology|December 27, 2015
Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based TherapyEric Van Cutsem, Florence Joulain, Paulo M Hoff, et al.
International Journal of Technology Assessment in Health Care|May 5, 2022
Health Technology Assessment in Support of National Health Insurance in South AfricaMaryke Wilkinson, Andrew Lofts Gray, Roger Wiseman, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
The Oncologist|March 11, 2022
The Impact of Breast Cancer Treatment Delays on Survival Among South African WomenYoanna S Pumpalova, Oluwatosin A Ayeni, Wenlong Carl Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME studyJean-Yves Douillard, Salvatore Siena, James Cassidy, et al.
Plos One|February 16, 2023
Drivers of disparities in stage at diagnosis among women with breast cancer: South African breast cancers and HIV outcomes cohortWitness Mapanga, Shane A Norris, Ashleigh Craig, et al.
International Journal of Cancer|February 26, 2022
Impact of HIV infection on survival among women with stage I-III breast cancer: Results from the South African breast cancer and HIV outcomes studyOluwatosin A Ayeni, Daniel S O'Neil, Yoanna S Pumpalova, et al.
The Oncologist|March 21, 2023
The Impact of HIV Infection on Neoadjuvant and Adjuvant Chemotherapy Relative Dose Intensity in South African Patients with Breast CancerDaniel S O'Neil, Oluwatosin A Ayeni, Hayley A Farrow, et al.
The Lancet. Global Health|November 22, 2024
The association of HIV status with triple-negative breast cancer in patients with breast cancer in South Africa: a cross-sectional analysis of case-only data from a prospective cohort studyJacob Dubner, Alfred I Neugut, Maureen Joffe, et al.
Breast Cancer Research : BCR|January 23, 2023
Multimorbidity and overall survival among women with breast cancer: results from the South African Breast Cancer and HIV Outcomes StudyOluwatosin A Ayeni, Maureen Joffe, Witness Mapanga, et al.
The New England Journal of Medicine|September 13, 2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancerJean-Yves Douillard, Kelly S Oliner, Salvatore Siena, et al.
Targeted Oncology|December 27, 2015
Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based TherapyEric Van Cutsem, Florence Joulain, Paulo M Hoff, et al.
International Journal of Technology Assessment in Health Care|May 5, 2022
Health Technology Assessment in Support of National Health Insurance in South AfricaMaryke Wilkinson, Andrew Lofts Gray, Roger Wiseman, et al.
Pageof 10